Skin cancer, particularly melanoma, has traditionally been treated with surgery, but recent advancements in therapies such as checkpoint inhibitors have significantly improved survival rates. Melanoma vaccines are emerging as a promising treatment option, especially when combined with other cancer drugs. Melanoma arises from melanocytes, the pigment-producing cells in the skin, and its uncontrolled growth can lead to fatal consequences if left untreated. However, the development of personalized mRNA vaccines has opened new avenues for melanoma treatment, showing great potential in clinical trials.
Two leading candidates in the melanoma mRNA vaccine race are Moderna and Merck’s mRNA-4157 and BioNTech’s BNT111. Moderna’s mRNA-4157, in partnership with Merck, utilizes lipid nanoparticles to deliver mRNA into cells, instructing them to produce proteins that trigger the immune system to recognize tumor neoantigens. Clinical trials have demonstrated impressive results, with a significant increase in overall survival rates and a reduced risk of recurrence or metastasis when combined with Merck’s Keytruda checkpoint inhibitor.
BioNTech’s BNT111, developed in collaboration with Regeneron, encodes melanoma-associated antigens to stimulate T-cell responses against these antigens. Positive results from a phase 2 trial have shown an improvement in the overall response rate in patients treated with BNT111 in combination with Libtayo. The vaccine received orphan drug designation and fast track status from the FDA, underscoring its potential as a melanoma treatment option.
Scancell’s DNA vaccines, SCIB1 and iSCIB1+, have shown promising results in combination with checkpoint inhibitors in patients with advanced melanoma. The ongoing phase 2 trial has demonstrated high response rates, with plans to publish further survival data later this year. Evaxion Biotech’s personalized peptide-based cancer vaccine, EVX-01, aims to engage the immune system in fighting cancer by targeting each patient’s unique tumor profile and immune characteristics. Initial trial data has shown a high tumor-specific immune response, positioning EVX-01 as a potential standalone treatment for advanced melanoma.
Combination therapies involving cancer vaccines and checkpoint inhibitors are proving to be effective in treating melanoma. The use of mRNA technology in cancer vaccines is gaining momentum, with a projected significant market growth in the coming years. As these innovative vaccine candidates progress through clinical trials, there is optimism about their potential to transform melanoma treatment and improve patient outcomes.
Tags: cell therapy, lipid nanoparticles, biotech
Read more on labiotech.eu